The American group AbbVie announces the acquisition of compatriot Allergan, maker of Botox, for about 63 billion dollars (55.3 billion euros).
New big acquisition in the biotechnology sector. Abbvie
, a former Galapagos partner and current partner of Argenx, says Allergan for $ 63 billion. he offers US $ 188.24 per share of Allergan
, a 45% premium over the closing price on Monday. His offer consists of 0.8660 of the AbbVie title and $ 120.30 in cash.
Allergan announced earlier this month that a decision would be taken in the next two months regarding a possible division of activities.
Under pressure from investors to restructure their business, Allergan announced in early June that a decision would be taken over the next two months regarding a possible division of activities.
Allergan shares closed Monday at $ 129.57 on Wall Street. On Tuesday, it rose 25.36% on Wall Street, flirting with $ 163. AbbVie stock fell more than 16% in the New York market.
The details of the merged entity's future
The combined entity shall display an annual turnover of 48 billion dollars. The operation should also increase adjusted earnings per share by 10% in the first year after completion, specified the two groups.
The new set will be directed by Richard A. Gonzalez, the head of AbbVie. The headquarters will remain in Delaware. Two members of Allergan's Board of Directors, including General Manager Brent Saunders, will join the board of directors of the new group as soon as the new entity is created.
The new group will be present in 175 countries.
Biopharma, target of acquisitions
Big acquisitions are growing in the biopharmaceutical sector who is constantly trying find innovative treatments for cancer and other diseases; developments that require massive investments, but can compensate.
Japanese Takeda Pharmaceutical Co also this year finalized the recovery for some US $ 62 billion of Shire Plc.
We will also remember Sanofi, which last year won Bioverativ for US $ 11.6 billion; and having already disbursed almost 4 billion euros for Ablynx.